Antibody-drug conjugates in lung cancer: current landscape and future perspectives.

PURPOSE OF REVIEW Antibody-drug conjugates (ADCs) have emerged as a significant therapeutic class in lung cancer, integrating the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. This review delineates ADC structure, mechanisms of action, and clinical advancements in nonsmall-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), with a focus on novel bispecific formats to address tumor heterogeneity and therapeutic approaches to overcome resistance mechanisms. RECENT FINDINGS Multiple ADCs have demonstrated significant clinical activity in biomarker-defined patient subsets. The human epidermal growth factor receptor 2 (HER2)-targeted ADC trastuzumab deruxtecan has demonstrated unprecedented efficacy in HER2-mutant NSCLC, resulting in global regulatory approvals. Novel ADC targets such as TROP2, HER3, MET, CEACAM5, integrin β6, DLL3, B7-H3, and SEZ6 are undergoing clinical evaluation. Advancements in payload design, linker stability, and conjugation methodologies have enhanced therapeutic indices. Concurrently, bispecific ADCs are emerging to address challenges posed by intratumoral heterogeneity and antigen-loss-mediated resistance mechanisms. SUMMARY ADCs are transforming lung cancer therapy by delivering potent cytotoxics with manageable safety. Next-generation bispecific and biparatopic formats may broaden eligibility, improve tumor penetration, and delay resistance. Incorporating predictive biomarkers and real-time monitoring will be key to their use in earlier disease and to establishing ADCs as a cornerstone of precision oncology.

• Publication year

  2025

• Venue

  Current Opinion in Oncology

• Publication date

  2025-10-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/CCO.0000000000001200PMID 41222552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The next generation of immunotherapies for lung cancers

  2025cited by this paper
• Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer

  2025cited by this paper
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

  2025cited by this paper
• Antibody-drug conjugates in cancer therapy: applications and future advances

  2025cited by this paper
• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

  2025cited by this paper
• Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies

  2025cited by this paper
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

  2025cited by this paper
• Recent advances in therapeutic strategies for non-small cell lung cancer

  2025cited by this paper
• Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.

  2025cited by this paper
• Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

  2025cited by this paper
• Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.

  2025cited by this paper
• Assessment of targets of antibody drug conjugates in SCLC

  2025cited by this paper
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

  2025cited by this paper
• A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC.

  2025cited by this paper
• Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

  2024cited by this paper
• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

  2024cited by this paper
• Cancer therapy with antibodies

  2024cited by this paper
• Antibody-drug conjugates: Principles and opportunities.

  2024cited by this paper
• Resistance to antibody–drug conjugates: A review

  2024cited by this paper
• The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review

  2024cited by this paper
• Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses

  2024cited by this paper
• OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial

  2024cited by this paper
• OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01

  2024cited by this paper
• Monoclonal Antibodies for the Treatment of Ocular Diseases

  2024cited by this paper
• 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study

  2024cited by this paper
• 642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC

  2024cited by this paper
• A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

  2024cited by this paper
• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

  2024cited by this paper
• Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.

  2024cited by this paper
• ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).

  2024cited by this paper
• Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).

  2024cited by this paper
• Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study

  2024cited by this paper
• Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.

  2024cited by this paper
• Bispecific antibody drug conjugates: Making 1+1>2

  2024cited by this paper
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cited by this paper
• HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.

  2023cited by this paper
• Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates

  2023cited by this paper
• 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors

  2023cited by this paper
• Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

  2023cited by this paper
• Exploration of the antibody–drug conjugate clinical landscape

  2023cited by this paper
• SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications

  2023cited by this paper
• Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

  2023cited by this paper
• Antibody–drug conjugates: Recent advances in payloads

  2023cited by this paper
• First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

  2023cited by this paper
• TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

  2023cited by this paper
• Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.

  2023cited by this paper
• Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.

  2023cited by this paper
• Mechanisms of Resistance to Antibody-Drug Conjugates

  2023cited by this paper
• HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.

  2023cited by this paper
• Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

  2023cited by this paper
• Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

  2022cited by this paper
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy

  2022cited by this paper
• The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer

  2022cited by this paper
• FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.

  2022cited by this paper
• HER3 in cancer: from the bench to the bedside

  2022cited by this paper
• Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

  2022cited by this paper
• Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.

  2021cited by this paper
• Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.

  2021cited by this paper
• Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

  2021cited by this paper
• Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

  2021cited by this paper
• EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

  2021cited by this paper
• Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

  2021cited by this paper
• Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

  2021cited by this paper
• Antibody–Drug Conjugates—A Tutorial Review

  2021cited by this paper
• Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

  2021cited by this paper
• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

  2021cited by this paper
• How to select IgG subclasses in developing anti-tumor therapeutic antibodies

  2020cited by this paper
• The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals

  2020cited by this paper
• Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

  2020cited by this paper
• CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration

  2020cited by this paper
• HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers.

  2020cited by this paper
• Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

  2019cited by this paper
• Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly

  2019cited by this paper
• Cleavable linkers in antibody-drug conjugates.

  2019cited by this paper
• Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

  2018cited by this paper
• Bispecifics and antibody-drug conjugates: A positive synergy.

  2018cited by this paper
• Application of Immuno-PET in Antibody–Drug Conjugate Development

  2018cited by this paper
• First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

  2018cited by this paper
• Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

  2017cited by this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cited by this paper
• Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

  2017cited by this paper
• GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

  2017cited by this paper
• Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

  2016cited by this paper
• HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

  2016cited by this paper
• Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

  2016cited by this paper
• Antibody-drug conjugates: recent advances in conjugation and linker chemistries

  2016cited by this paper
• Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

  2016cited by this paper
• Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63

  2016cited by this paper
• Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

  2015cited by this paper
• Bispecific antibodies.

  2015cited by this paper
• Mechanisms of action of therapeutic antibodies for cancer.

  2015cited by this paper
• Advances in the treatment of non-small cell lung cancer.

  2014cited by this paper
• Linker technologies for antibody-drug conjugates.

  2013cited by this paper
• Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis

  2013cited by this paper
• Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

  2012cited by this paper
• Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

  2012cited by this paper
• Expression and mutational analysis of MET in human solid cancers

  2008cited by this paper
• A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer

  2007cited by this paper
• A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.

  2007cited by this paper
• Chemotherapy and the war on cancer

  2005cited by this paper

• No citing papers are available for this paper.